Skip to main content

Table 2 Baseline characteristics with number of patients

From: Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2

  Meperidinea (N = 42) Tramadolb (N = 49)  
N pts % N pts % p-value
Race      0.177
 White 43 88% 36 86%  
 Hispanic 3 6% 4 10%  
 American Indian 3 6% 0 0%  
 Unknown 0 0% 2 5%  
Gender      0.232
 Female 14 29% 17 40%  
 Male 35 71% 25 60%  
Previous treatment 17 35% 7 17% 0.052
Malignancy      0.088
 Renal Cell Carcinoma 39 80% 26 63%  
Melanoma 10 20% 15 37%  
Tramadol 10 24% 49 100% < 0.001
  1. aGroup 1 includes patients who were pretreated with meperidine
  2. bGroup 2 included those who were pretreated with tramadol